A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.

Key facts

Study ID

NCT07489599

Run by

Qilu Pharmaceutical Co., Ltd.

People needed

68

Starts

2026-03-01

Expected to finish

2027-03-01

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.